

Dr. Veerendra Koppolu, M.Sc Ph.D C.Cy
Senior Scientist
AstraZeneca/MedImmune
Gaithersburg, MD, USA
Phone: 678-697-9216
Email: veeru.bios@gmail.com



Research Interest:

Pre-clinical and clinical development of monoclonal antibodies and novel small molecules as breakthrough therapies for cancer and infectious diseases. Characterization and Potency evaluation of drugs and vaccines.

Biography:

Veerendra Koppolu M.Sc Ph.D C.Cy is a senior scientist in the Department of Biologics Development at AstraZeneca/MedImmune in Gaithersburg, Maryland, USA. Dr. Koppolu is also a honorary faculty member at non-profit organization Novel Global Community Education Foundation (NGCEF) focused in guiding doctoral students. His lectures are highly valued and was awarded Robert H Emmer award and Michael S Gaines awards for this teaching. Dr. Koppolu has published over 50 peer-reviewed papers including research article, review articles, abstracts, book chapters, and books. Dr. Koppolu is serving as reviewer of 30 peer-reviewed international journals including Biotechnology Journal, Journal of Bacteriology, Future microbiology etc. Dr. Koppolu was listed in top 1% peer reviewers and awarded as best peer reviewer in Molecular Biosciences for the year 2017 by publons. Dr. Koppolu is Editorial advisory board member of *International Journal of Applied and Natural Sciences*, Editor of *Oncology Reports and Reviews*, Editor of *Holistic Approaches in Oncotherapy*, Editor of *Open Access Journal of Surgery*, Associate Editor of *Cancer Therapy and Oncology International Journal*, Associate Editor of *Research Reviews on healthcare*. Dr. Koppolu is a member in international scientific communities such as "American chemical society, American Society of Microbiology, American Association of cancer research, American Society of clinical oncology, and International certified flow cytometry Association. His primary research interests include pre-clinical and clinical development of immunotherapeutic drugs including monoclonal antibodies, bispecifics, and antibody drug conjugates. At AstraZeneca, he helped in the development of drug Durvalumab, an FDA approved drug that prevents tumor immune suppression in urinary bladder cancer. He also worked in the development of immunotherapeutic vaccines for triple negative breast cancer. Dr. Koppolu holds a BS and M.Sc (Biotech) from India, PhD from University of Kansas (USA), and a certification in Flow Cytometry (C.Cy)

- [Veerendra Koppolu, Veneela KR Vasigala \(2016\) CTLA-4 Antibodies in Cancer Immunotherapy. MOJ Immunol 3\(3\): 00092.](#)

- **Veerendra Koppolu**, Veneela KR Vasigala (2016) Nivolumab in the treatment of Metastatic Melanoma. (Accepted, Journal of Cancer Research and Therapeutics)
- SriHari Raju Mulagapati, **Veerendra Koppolu**, Raju T Shantha (2017) Decoding of O-linked Glycosylation by Mass Spectrometry. *Biochemistry*, **2017**, 56 (9), pp 1218–1226
- **Veerendra Koppolu**, Veneela KR Vasigala (2017) Cancer Immunotherapy Arsenal: Current and Promising New Approaches. *Cancer Therapy and Oncology International Journal*. Volume 5 Issue 3 - May 2017
- **Veerendra Koppolu**, Ichie Osaka, Jeff M. Skredenske, Bria Kettle, Scott Hefty and Susan M. Egan “Small molecule inhibitor of *Shigella flexneri* master virulence regulator, VirF”. *Infect Immun.* 2013 Nov;81(11):4220-31.
- Jeff M. Skredenske, **Veerendra Koppolu**, Ana Kolin, James Deng, Bria Kettle, Byron Taylor and Susan M. Egan “Identification of a small molecule inhibitor of bacterial AraC family activators”. *J Biomol Screen.* 2013 Jun;18(5):588-98. (PMID: 23364515)
- **Veerendra Koppolu** and Susan M. Egan “Small molecule inhibitor of *Shigella flexneri* master virulence regulator, VirF”. 7th Asia-Pacific Biotech Congress 2015, China. Abstract
- **Veerendra Koppolu** and Veneela KR Vasigala. "Role of Escherichia coli in Biofuel Production." *Microbiology Insights* 9 (2016): 29.